<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-134391" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atypical Antipsychotic Effect on Bone Mineral Density</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Jumaili</surname>
            <given-names>Wisam</given-names>
          </name>
          <aff>Texas Tech University Health Science</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Shailesh B.</given-names>
          </name>
          <aff>Texas Tech Health Science Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Wisam Al Jumaili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shailesh Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-134391.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atypical antipsychotic use in psychiatric patients, particularly children and adolescents (C/A), has increased recently. Autism spectrum, bipolar, psychosis, and other psychiatric or emotional disorders are psychiatric conditions that need Antipsychotics today. There is limited data on the long-term safety of Antipsychotics on growth and development, specifically on bone metabolism. This activity outlines the clinical presentation, evaluation, and management by an interprofessional team of atypical antipsychotics induced bone changes in children and adults.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Provide the summary of the indications for antipsychotics agents.</p></list-item><list-item><p>Describe the mechanism of atypical antipsychotics-induced bone changes.</p></list-item><list-item><p>Review the clinical presentation and differential diagnosis of impaired bone mineral density.</p></list-item><list-item><p>Emphasize the importance of early recognition and treatment options used by the interprofessional team for the atypical antipsychotics-induced bone changes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=134391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=134391">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-134391.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>According to the National Research Council and Institute of Medicine, about 14% to 20% of&#x000a0; C/A have a psychiatric illness.&#x000a0;Up to 80% of these C/A are on multiple psychotropics simultaneously, including atypical antipsychotics.&#x000a0;The US - FDA has approved the use of antipsychotics in specific psychiatric disorders include Tourette's and other tics disorders, behavioral and emotional symptoms associated with developmental delay, autistic spectrum disorder, bipolar disorder, and schizophrenia.&#x000a0;Also, significant off-label antipsychotic uses (without FDA approval) are of the standard of practice today to manage C/A emotional and behavioral symptoms.<xref ref-type="bibr" rid="article-134391.r1">[1]</xref></p>
        <p>A metanalysis reported a median prevalence of antipsychotics use in autism spectrum C/A of about 17%. Risperidone is the most commonly prescribed antipsychotic (55%), followed by aripiprazole (35%).<xref ref-type="bibr" rid="article-134391.r2">[2]</xref>&#x000a0;While the antipsychotics trending pattern in adult psychiatric inpatient show olanzapine prescribed chiefly (51%) followed by risperidone (23%).<xref ref-type="bibr" rid="article-134391.r3">[3]</xref>&#x000a0;Antipsychotics cause various endocrine and metabolic side effects, including overweight, hyperlipidemia, uncontrolled diabetes, and hyperprolactinemia.<xref ref-type="bibr" rid="article-134391.r4">[4]</xref>&#x000a0;Hyperprolactinemia and movement disorder side effects are common with first-generation antipsychotics due to potent dopamine receptor blocking effects.<xref ref-type="bibr" rid="article-134391.r5">[5]</xref>&#x000a0;</p>
        <p>Studies indicate that up to two-thirds of patients treated with atypical antipsychotics experience impaired bone marrow density, leading to osteoporosis.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;The risk of bone disease and bone fracture positively correlates to this category of medication. Antipsychotics can directly alter bone mineral density or indirectly cause obesity due to limited physical activity or excessive somnolence.<xref ref-type="bibr" rid="article-134391.r7">[7]</xref><xref ref-type="bibr" rid="article-134391.r8">[8]</xref>&#x000a0;Evidence shows early onset osteoporosis in patients with mental illness like schizophrenia related to chronic exposure to antipsychotics.<xref ref-type="bibr" rid="article-134391.r9">[9]</xref> Antipsychotics use causes an increased risk of hip fracture up to 1.6 times.<xref ref-type="bibr" rid="article-134391.r9">[9]</xref>&#x000a0;The US-FDA cautions in the prescribing package insert of this adverse effect.<xref ref-type="bibr" rid="article-134391.r2">[2]</xref></p>
      </sec>
      <sec id="article-134391.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Antipsychotics cause detrimental effects on bone growth. Antipsychotics negatively affect bone metabolism by blocking dopamine receptors, causing hyperprolactinemia and hypogonadotropic hypogonadism. Hyperprolactinemia directly affects bone growth through prolactin receptors on the osteoblast, regardless of the gonadotrophic hormonal level.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;</p>
        <p>The high prolactin levels can lower calcium absorption and activate parathyroid hormone-related peptides, which increase bone resorption. Antipsychotics can also delay bone maturation by modulating serotoninergic and adrenergic receptors on the osteoblast and osteoclast cells.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;</p>
        <p>High cortisol levels are frequently seen in psychiatric patients on antipsychotics, adding another risk factor for impaired bone mineralization.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;Patients on multiple psychotropic medications like antipsychotics and SSRI are at higher risk for deformed bones.<xref ref-type="bibr" rid="article-134391.r10">[10]</xref>&#x000a0;Finally, adolescents with severe chronic mental health conditions are at increased risk for low vitamin D levels due to poor diet, limited physical activities, low sun exposure, and high substance use, which increase vulnerability to exaggerated detrimental effects of antipsychotics on bone mineralization.<xref ref-type="bibr" rid="article-134391.r11">[11]</xref><xref ref-type="bibr" rid="article-134391.r12">[12]</xref></p>
      </sec>
      <sec id="article-134391.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Osteoporosis affects about 200 million people globally.&#x000a0;Osteoporosis causes one fracture every 3 seconds.<xref ref-type="bibr" rid="article-134391.r13">[13]</xref>&#x000a0;Primary osteoporosis is an aging process. However, secondary osteoporosis is widespread among the young.&#x000a0;Chronic exposure to neuroleptic/antipsychotics can cause secondary osteoporosis.<xref ref-type="bibr" rid="article-134391.r13">[13]</xref>&#x000a0;About 85% of critical bone growth occurs before the age of 18, and a loss of 5&#x000a0;to 10 % of the peak bond density can significantly increase the chance of fractures or bone disease later in life.<xref ref-type="bibr" rid="article-134391.r10">[10]</xref>&#x000a0;</p>
        <p>One study found that 44% of the male and 48.9% of the female schizophrenia patients have osteopenia compared to 9.2% male and 21% female without schizophrenia.&#x000a0;Elderly patients with schizophrenia have a double risk of osteoporosis than a matched control.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;Up to 65% of patients on antipsychotics endure osteopenia (bone loss), with a subsequent higher risk of future osteoporosis. Antipsychotics raise prolactin levels and consequent osteoporosis affects males and females equally.<xref ref-type="bibr" rid="article-134391.r14">[14]</xref>&#x000a0;Although osteoporosis is miscalled as "women's disease."<xref ref-type="bibr" rid="article-134391.r14">[14]</xref>&#x000a0;</p>
        <p>No significant sex difference in terms of antipsychotic-induced&#x000a0;bone mineralization defect was observed since hyperprolactinemia has inhibitory effects on gonadotrophins level.&#x000a0;However, hyperprolactinemia prevalence is higher in postmenopausal females.&#x000a0;Risperidone causes the early-onset and prolonged duration of hyperprolactinemia.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref></p>
      </sec>
      <sec id="article-134391.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Osteopenia is called a 'silent disease' as it is often asymptomatic until a fracture develops.<xref ref-type="bibr" rid="article-134391.r14">[14]</xref>&#x000a0;Nonspecific clinical presentation may be the reason for a delayed diagnosis.&#x000a0;Typical clinical presentation of impaired bone mineral density includes diffuse bone pain, tenderness, muscle weakness, and fragility fractures. The fracture patterns in osteomalacia (bone mineral density or BMD over 1 but less than 2.5 SD) are typically different from osteoporosis (standard deviations 2.5 times below the healthy population T-score).&#x000a0;Fragility fractures of the pelvic bone, foot, tibial, and ribs bone are signs of osteomalacia. The neck of the femur and wedged vertebral fractures are classic osteoporosis.<xref ref-type="bibr" rid="article-134391.r15">[15]</xref></p>
      </sec>
      <sec id="article-134391.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Currently available modalities used to assess BMD include metacarpal morphometry, quantitative bone ultrasound (QUS), quantitative computed tomography (QCT), and dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI) bone density.&#x000a0;A plain skeletal radiograph detects BMD when the bone loss exceeds 40% and hence insensitive for routine clinical use.&#x000a0;QCT measures the bone volume and accurately assesses volumetric BMD, and it can differentiate between cortical and trabecular bone.</p>
        <p>Peripheral (PQCT) is an alternative technique with less radiation risk and is more convenient for children.&#x000a0;DXA is the primary tool for assessing bone density. It has low radiation exposure, precise results, and lower cost than QCT. However, it does not directly measure actual volume or assessing BMD, and rarely bone biopsy may be needed to confirm the diagnosis.<xref ref-type="bibr" rid="article-134391.r8">[8]</xref></p>
      </sec>
      <sec id="article-134391.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Practice guidelines are lacking for testing for prolactin level or bone assessment during APs exposure. Besides, there is no clear correlation between antipsychotics, prolactin level concentration, and skeletal complications in children or adults.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;There is no clear correlation between the patient's age, duration of treatment, and sex or race with BMD in the psychiatric population compared to the general population.<xref ref-type="bibr" rid="article-134391.r7">[7]</xref>&#x000a0;</p>
        <p>Proactive preventive measures to improve BMD in psychiatric patients chronically treated with antipsychotics, including lifestyle modification, fall prevention program, monitoring prolactin level, vitamin D supplement, avoid smoking, and alcohol exposure.<xref ref-type="bibr" rid="article-134391.r16">[16]</xref>&#x000a0;</p>
        <p>Mechanical stimulation of bone through whole-body vibration therapy may provide positive results. <xref ref-type="bibr" rid="article-134391.r17">[17]</xref>&#x000a0;Medications like bisphosphonate, raloxifene, denosumab, and glucagon-like peptide-1 (GLP-1) are currently utilized in clinical practice.<xref ref-type="bibr" rid="article-134391.r16">[16]</xref><xref ref-type="bibr" rid="article-134391.r18">[18]</xref><xref ref-type="bibr" rid="article-134391.r19">[19]</xref><xref ref-type="bibr" rid="article-134391.r20">[20]</xref>&#x000a0;Moreover, teriparatide, anabolic, and hormonal replacement therapy are other options to improve bone mineral density.<xref ref-type="bibr" rid="article-134391.r17">[17]</xref><xref ref-type="bibr" rid="article-134391.r21">[21]</xref><xref ref-type="bibr" rid="article-134391.r22">[22]</xref></p>
      </sec>
      <sec id="article-134391.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Low bone mineral density like osteoporosis or osteomalacia could be a primary condition or appear secondary due to the following factors or conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Endocrine disorders like hypogonadism, pituitary disorders, diabetes mellitus, thyrotoxicosis.<xref ref-type="bibr" rid="article-134391.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Autoimmune and chronic diseases like rheumatic disorders, chronic renal, pulmonary, gastrointestinal diseases, transplantation, granulomatous diseases.</p>
          </list-item>
          <list-item>
            <p>Bone marrow and malignant disorders, multiple myeloma, lymphomas and leukemias, metastatic bone disease, chronic anemia.<xref ref-type="bibr" rid="article-134391.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Medications like glucocorticoid excess, anticonvulsants, antituberculosis agent, long-term heparin, cyclosporin A, or methotrexate.</p>
          </list-item>
          <list-item>
            <p>Nutritional and deficiency like vitamin K, D, C, and malnutrition.</p>
          </list-item>
          <list-item>
            <p>Genetic disorders like osteogenesis imperfect, homocystinuria, Ehlers-Danlos syndrome, and Marfan syndrome.</p>
          </list-item>
          <list-item>
            <p>Other factors like smoking, alcoholism, immobilization, and weight loss.<xref ref-type="bibr" rid="article-134391.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-134391.s9" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Yvette Roke et al. (2012), in a retrospective observational study, reported lower lumbar spine bone density in antipsychotic-treated boys (n = 56) with hyperprolactinemia compared to the non-antipsychotics treated control (n = 47), with a mean duration of 52 months antipsychotics exposure.<xref ref-type="bibr" rid="article-134391.r24">[24]</xref>&#x000a0;[Level 4]&#x000a0;While Bonnot et al. (2011), in a retrospective observational study of 136 institutionalized adolescents, found significant vitamin-D deficiency unrelated to the specific antipsychotics (level IV).<xref ref-type="bibr" rid="article-134391.r15">[15]</xref>&#x000a0;</p>
        <p>Calarge et al. (2010) have reported a significant reduction in BMD in adolescents with risperidone and SSRI combination induced hyperprolactinemia compared to controls with risperidone exposure only. A three-year cross-sectional retrospective observational study (n = 108 boys, mean age = 11.7 years) was enrolled with DSM-IV clinical diagnoses.<xref ref-type="bibr" rid="article-134391.r11">[11]</xref>&#x000a0;[Level 4]</p>
        <p>In a retrospective observational study, Al-Omran et al. (2016) found that over 80% of adult psychiatric patients on chronic antipsychotic have low bone mineral density, and 44% of patients were osteoporotic, and 45% were osteopenic.<xref ref-type="bibr" rid="article-134391.r13">[13]</xref>&#x000a0;[Level 4]</p>
      </sec>
      <sec id="article-134391.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of the antipsychotics-induced impaired bone mineral density is good if it is detected early and managed properly.<xref ref-type="bibr" rid="article-134391.r13">[13]</xref>&#x000a0;However, chronic pain, osteomalacia, osteoporosis, and bone fracture are common sequels if the condition is left untreated.<xref ref-type="bibr" rid="article-134391.r6">[6]</xref>&#x000a0;High morbidity and mortality are associated with a bone fracture in psychiatric patients.<xref ref-type="bibr" rid="article-134391.r25">[25]</xref><xref ref-type="bibr" rid="article-134391.r26">[26]</xref>&#x000a0;The risk of complications can be minimized with lifestyle changes, exercise, and a well-balanced diet.<xref ref-type="bibr" rid="article-134391.r16">[16]</xref>&#x000a0;And or add-on medications.<xref ref-type="bibr" rid="article-134391.r24">[24]</xref></p>
      </sec>
      <sec id="article-134391.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Antipsychotics can cause various metabolic and hormonal side effects, including obesity, dyslipidemia, uncontrolled diabetes mellitus, metabolic syndrome, QTc abnormality, and the extrapyramidal sequel, myocarditis, bone marrow suppression, cataracts, hyperprolactinemia with or without hypogonadism, and sexual adverse effects.<xref ref-type="bibr" rid="article-134391.r8">[8]</xref><xref ref-type="bibr" rid="article-134391.r11">[11]</xref>&#x000a0;</p>
        <p>Impaired bone mineral density with or without bone fracture is one of the potential APs side effects that the clinician has not thoroughly studied and missed. Antipsychotics medications diffuse to both the bone marrow and the central nervous system. Consequently, antipsychotics related bone disease or fracture could be a consequence of direct and indirect adverse effects on bone turnover.<xref ref-type="bibr" rid="article-134391.r2">[2]</xref>&#x000a0;</p>
        <p>Frequent studies refereed to this correlation [see pertinent studies section]. Given the large patient population that is taking these medications.<xref ref-type="bibr" rid="article-134391.r1">[1]</xref>&#x000a0;Understanding the level of risk, proper recognition, and possible early preventing or treatment of drug-induced bone changes is essential for clinicians and patient populations.</p>
      </sec>
      <sec id="article-134391.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The patient family should be more oriented to bone mineral density complications.<xref ref-type="bibr" rid="article-134391.r15">[15]</xref><xref ref-type="bibr" rid="article-134391.r4">[4]</xref>&#x000a0;Consultation with a psychiatrist or a pharmacist can assist with antipsychotics selection, guide the ideal dosing, and explore safer alternatives. Providers should be aware of the need for early assessment of possible adverse effects from the antipsychotics, employ early screening, and prevent iatrogenic complications.<xref ref-type="bibr" rid="article-134391.r27">[27]</xref><xref ref-type="bibr" rid="article-134391.r5">[5]</xref>&#x000a0;A team approach should be applied with the involvement of mental health providers with open communication between the inter-professional team member and the patient's family.<xref ref-type="bibr" rid="article-134391.r28">[28]</xref></p>
      </sec>
      <sec id="article-134391.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians should be aware of the potential adverse effects of antipsychotics on bone mineral density, especially in children and elderly patients who are physically and emotionally more prone to the medication's side effects due to their body size, different metabolism rate, and evolving physiology.<xref ref-type="bibr" rid="article-134391.r24">[24]</xref> Antipsychotic-exposed patients should have frequent&#x000a0;screening, especially with concomitant hyperprolactinemia.<xref ref-type="bibr" rid="article-134391.r15">[15]</xref>&#x000a0;</p>
        <p>Providers need to utilize a more sensitive diagnostic tool like QUS, PQCT, MRI Bone density to screen and assess the BMD in children and adults.<xref ref-type="bibr" rid="article-134391.r11">[11]</xref><xref ref-type="bibr" rid="article-134391.r8">[8]</xref> Volumetric BMD is a more sensitive indicator of mineral density for growing children considering their height and pubertal stage.&#x000a0;The physicians should educate the patient's family about the potential long-term side effects of antipsychotics and evaluate calcium and phosphorus intake, sun exposure, vitamin D level, bone turnover markers like alkaline phosphatase, and physical activity.<xref ref-type="bibr" rid="article-134391.r15">[15]</xref><xref ref-type="bibr" rid="article-134391.r4">[4]</xref>&#x000a0;</p>
        <p>The antipsychotic&#x000a0;dose should&#x000a0;be adjusted if clinically safe and suitable. Prolactin levels should be checked at baseline and then regularly annually and should be normalized promptly. A switch to antipsychotics without prolactin-elevating qualities may be a useful alternative and or add-on antiresorptive medications.<xref ref-type="bibr" rid="article-134391.r24">[24]</xref><xref ref-type="bibr" rid="article-134391.r15">[15]</xref><xref ref-type="bibr" rid="article-134391.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-134391.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=134391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=134391">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/atypical-antipsychotic-effect-on-bone-mineral-density/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=134391">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/134391/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=134391">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-134391.s15">
        <title>References</title>
        <ref id="article-134391.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Cluxton-Keller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic medication prescribing trends in children and adolescents.</article-title>
            <source>J Pediatr Health Care</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-45</page-range>
            <pub-id pub-id-type="pmid">22360933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Al&#x000f2;</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>De Crescenzo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Minozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morgano</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Mitrova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Scattoni</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;nemann</surname>
                <given-names>HJ</given-names>
              </name>
              <collab>ISACA guideline working group</collab>
            </person-group>
            <article-title>Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review.</article-title>
            <source>Health Qual Life Outcomes</source>
            <year>2020</year>
            <month>Apr</month>
            <day>16</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <pub-id pub-id-type="pmid">32299432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niedrig</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>G&#x000f6;tt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bucklar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Russmann</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Second-generation antipsychotics in a tertiary care hospital: prescribing patterns, metabolic profiles, and drug interactions.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-50</page-range>
            <pub-id pub-id-type="pmid">26473524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calarge</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Bone Mass in Boys with Autism Spectrum Disorder.</article-title>
            <source>J Autism Dev Disord</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>1749</fpage>
            <page-range>1749-1755</page-range>
            <pub-id pub-id-type="pmid">28342168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stroup</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of common adverse effects of antipsychotic medications.</article-title>
            <source>World Psychiatry</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-356</page-range>
            <pub-id pub-id-type="pmid">30192094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences.</article-title>
            <source>Clin Psychopharmacol Neurosci</source>
            <year>2016</year>
            <month>Aug</month>
            <day>31</day>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-49</page-range>
            <pub-id pub-id-type="pmid">27489377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houseknecht</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Elucidating the Mechanism(s) Underlying Antipsychotic and Antidepressant-Mediated Fractures.</article-title>
            <source>J Ment Health Clin Psychol</source>
            <year>2017</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-13</page-range>
            <pub-id pub-id-type="pmid">31008454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roke</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>van Harten</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Buitelaar</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Tenback</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Quekel</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>de Rijke</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Boot</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>167</volume>
            <issue>6</issue>
            <fpage>855</fpage>
            <page-range>855-63</page-range>
            <pub-id pub-id-type="pmid">23011870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis associated with antipsychotic treatment in schizophrenia.</article-title>
            <source>Int J Endocrinol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>167138</fpage>
            <pub-id pub-id-type="pmid">23690768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calarge</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ivins</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Motyl</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Shibli-Rahhal</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bliziotes</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>278</fpage>
            <page-range>278-93</page-range>
            <pub-id pub-id-type="pmid">24167704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calarge</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ellingrod</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bliziotes</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>1685</fpage>
            <page-range>1685-90</page-range>
            <pub-id pub-id-type="pmid">22244026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lodhi</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Masand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shivakumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McAllister</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>O'Keane</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Sherwood</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Aitchison</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study.</article-title>
            <source>Schizophr Res</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>170</volume>
            <issue>2-3</issue>
            <fpage>245</fpage>
            <page-range>245-51</page-range>
            <pub-id pub-id-type="pmid">26792297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Omran</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Abu-Madini</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sadat-Ali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alfaraidy</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Shihada</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Low Bone Mass Secondary to Antipsychotic Medications.</article-title>
            <source>Saudi J Med Med Sci</source>
            <year>2016</year>
            <season>Sep-Dec</season>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>202</fpage>
            <page-range>202-205</page-range>
            <pub-id pub-id-type="pmid">30787730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f6;zen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>&#x000d6;z&#x00131;&#x0015f;&#x00131;k</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ba&#x0015f;aran</surname>
                <given-names>N&#x000c7;</given-names>
              </name>
            </person-group>
            <article-title>An overview and management of osteoporosis.</article-title>
            <source>Eur J Rheumatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-56</page-range>
            <pub-id pub-id-type="pmid">28293453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonnot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Inaoui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raffin-Viard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bodeau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Coussieu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Children and adolescents with severe mental illness need vitamin D supplementation regardless of disease or treatment.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-61</page-range>
            <pub-id pub-id-type="pmid">21486172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Assessing bone health in children and adolescents.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>Suppl 2</issue>
            <fpage>S205</fpage>
            <page-range>S205-12</page-range>
            <pub-id pub-id-type="pmid">23565379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Anabolic Therapy for the Treatment of Osteoporosis in Childhood.</article-title>
            <source>Curr Osteoporos Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>269</fpage>
            <page-range>269-276</page-range>
            <pub-id pub-id-type="pmid">29589203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maagensen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Fink-Jensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vilsb&#x000f8;ll</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.</article-title>
            <source>Psychiatry Res</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>296</volume>
            <fpage>113670</fpage>
            <pub-id pub-id-type="pmid">33373806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Raloxifene: a review of its use in postmenopausal osteoporosis.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>379</fpage>
            <page-range>379-411</page-range>
            <pub-id pub-id-type="pmid">10983739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eriksson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Broberg</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Ish&#x000f8;y</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Bak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Knop</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Ebdrup</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.</article-title>
            <source>Front Psychiatry</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>781</fpage>
            <pub-id pub-id-type="pmid">30745885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e4;&#x000e4;n&#x000e4;nen</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>H&#x000e4;rk&#x000f6;nen</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Estrogen and bone metabolism.</article-title>
            <source>Maturitas</source>
            <year>1996</year>
            <month>May</month>
            <volume>23 Suppl</volume>
            <fpage>S65</fpage>
            <page-range>S65-9</page-range>
            <pub-id pub-id-type="pmid">8865143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gambacciani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levancini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hormone replacement therapy and the prevention of postmenopausal osteoporosis.</article-title>
            <source>Prz Menopauzalny</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-20</page-range>
            <pub-id pub-id-type="pmid">26327857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taxel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Differential diagnosis and secondary causes of osteoporosis.</article-title>
            <source>Clin Cornerstone</source>
            <year>2000</year>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">10938988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiefenbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gehlen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwarz-Eywill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siebers-Renelt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Osteomalacia-Clinical aspects, diagnostics and treatment].</article-title>
            <source>Z Rheumatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>77</volume>
            <issue>8</issue>
            <fpage>703</fpage>
            <page-range>703-718</page-range>
            <pub-id pub-id-type="pmid">30097703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>De Hert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Manu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis and fracture risk in people with schizophrenia.</article-title>
            <source>Curr Opin Psychiatry</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>415</fpage>
            <page-range>415-29</page-range>
            <pub-id pub-id-type="pmid">22744405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stubbs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gaughran</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>De Hert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soundy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vancampfort</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-33</page-range>
            <pub-id pub-id-type="pmid">25666994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansur</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Medication Safety Systems and the Important Role of Pharmacists.</article-title>
            <source>Drugs Aging</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-21</page-range>
            <pub-id pub-id-type="pmid">26932714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-134391.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleury</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Grenier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bamvita</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Farand</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Relations between mental health team characteristics and work role performance.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>e0185451</fpage>
            <pub-id pub-id-type="pmid">28991923</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
